RIPE-KG · Version 1.1.0 · Resource
ripekg:work/RIPEW596368D59C3FE896
https://w3id.org/ripe/ripe-kg/work/RIPEW596368D59C3FE896
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1007%2Fs13318-014-0242-5The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties |
http://purl.org/spar/cito/cites |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
dcterms:title |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
node1 |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
rdfs:Resource |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
owl:Thing |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
prov:Entity |
ripekg:work/RIPEW596368D59C3FE896Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
rdf:type |
ripe:WorkWork |